UK
Symptom tracker
[ Ссылка ]
Over 4 million contributors
1,265 new cases per day
18, 933 symptomatic cases today
Data is consistent with the ONS household survey
ONS numbers slightly higher due to inclusion of asymptomatics
Symptomatic and asymptomatic cases
Down from last week
Localised outbreaks not spreading
Community spread continues
Lower death rates
[ Ссылка ]
Europe, cases rising
Severe complications and deaths remain relatively low
UK ventilated patients, 3,000 down to 70
Infection fatality rate
Is the severity of the disease decreasing a bit?
U Pittsburgh MC doctor says COVID-19 has become ‘less prevalent’ and isn’t making people as sick
[ Ссылка ]
Dr. Donald Yealy
All signs that we have available right now show that this virus is less prevalent than it was weeks ago
Among people who test positive, the total amount of the virus the patient has is much less than in the earlier stages of the pandemic
We see all of this as evidence that COVID-19 cases are less severe than when this first started
Virus mutating?
[ Ссылка ]
Triad of infectious disease, viral evolution
Study concluded that most mutations were neutral and did not affect viral lethality
Factors
Testing at an earlier stage of the illness
Social distancing, face coverings, hand and surface hygiene
Infection with lower viral load
Summer humidity reducing infection
Medical interventions more successful
Dexamethasone
Heparin
Becoming a disease of younger people
However
US, recent spike, 20s and 30s
Followed by a spike in older people
This could happen in UK and Europe in coming few weeks
US
Food and Drug Administration, emergency authorisation of convalescent plasma
Temporary emergency use authorization
[ Ссылка ]
[ Ссылка ]
Health care providers or acute care facilities, obtain COVID-19 convalescent plasma from an FDA-registered blood establishment
20,000 patients reviewed, safe
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
[ Ссылка ]
We are very uncertain whether convalescent plasma;
has any effect on all‐cause mortality at hospital discharge
prolongs time to death
has any effect on improvement of clinical symptoms at seven days
Safety
There is only very low‐certainty evidence for safety of convalescent plasma for COVID‐19
Allergic or respiratory problems
Transfusion‐associated dyspnoea
Transfusion‐related acute lung injury
